FindTrial
Sign In

CDKL3 in Osteosarcoma

The Role of CDKL3 in Osteosarcoma Proliferation and Progression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018088
Enrollment
Unknown
Registered
2018-08-29
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma

Interventions

High CDKL3 expression:None
Moderate CDKL3 expression:None
Low CDKL3 expression:None
Negative CDKL3 expression:None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed as osteosarcoma and received surgery at Shanghai Sixth People's Hospital since 2012.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Expression Level;—

Countries

China

Contacts

Public ContactAina He

Shanghai Sixth People's Hospital

aina.he@childrens.harvard.edu+86 18930172898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026